Table 1 Baseline characteristics of the study patients
Variable | OMT + CSWT group (n = 30) | OMT + sham procedure group (n = 29) | P value |
|---|---|---|---|
Demographic characteristics | |||
Age, years | 67.2 ± 7.8 | 69.4 ± 7.8 | 0.274 |
Male sex, n (%) | 19 (63.3) | 26 (89.7) | 0.018 |
Cardiovascular risk factors | |||
Hyperlipidaemia, n (%) | 30 (100) | 29 (100) | – |
Hypertension, n (%) | 29 (96.7) | 29 (100) | – |
Diabetes, n (%) | 8 (26.7) | 8 (27.6) | 0.937 |
Peripheral vascular disease, n (%) | 10 (33.3) | 12 (41.4) | 0.523 |
Current smoker, n (%) | 1 (3.3) | 4 (13.8) | 0.195 |
Positive family history for CVD, n (%) | 10 (33.3) | 19 (5.5) | 0.013 |
Medical history | |||
Previous myocardial infarction, n (%) | 15 (50.0) | 23 (79.3) | 0.019 |
Previous percutaneous intervention, n (%) | 16 (53.3) | 15 (51.7) | 0.902 |
Previous CABG, n (%) | 20 (66.7) | 18 (62.1) | 0.712 |
No revascularization, n (%) | 7 (23.3) | 7 (24.1) | 0.936 |
Three-vessel disease, n (%) | 24 (80.0) | 22 (75.9) | 0.161 |
Two-vessel disease, n (%) | 5 (16.7) | 2 (6.9) | |
Clinical parameters | |||
Body mass index, kg/m2 | 30.0 ± 4.3 | 30.3 ± 3.8 | 0.755 |
Angina episodes/week, median (25%;75%) | 5.5 (3.3; 14.8) | 7 (3.8; 15) | 0.500 |
Nitroglycerine consumption (times/week), median (25%;75%) | 2 (1; 2) | 2 (0; 5) | 0.250 |
Left ventricular ejection fraction (echocardiographic), % | 54.4 ± 9.5 | 56.0 ± 7.2 | 0.366 |
Systolic blood pressure, mmHg | 124.7 ± 20.9 | 128.1 ± 22.1 | 0.845 |
Diastolic blood pressure, mmHg | 81.1 ± 11.3 | 77.0 ± 11.2 | 0.341 |
Angina CCS class | |||
II, n (%) | 8 (26.7) | 9 (31.0) | 0.711 |
III, n (%) | 22 (73.3) | 20 (69.0) | |
Medical treatment | |||
ACE inhibitors / ARB, n (%) | 30 (100) | 29 (100) | – |
Beta-blocker, n (%) | 28 (93.1) | 27 (93.1) | 1 |
Long acting nitrates, n (%) | 19 (63.3) | 15 (51.7) | 0.367 |
Calcium channel blocker, n (%) | 16 (51.3) | 15 (51.7) | 0.902 |
Trimetazidine, n (%) | 20 (66.7) | 15 (51.7) | 0.243 |
Statins, n (%) | 30 (100) | 29 (100) | – |
Mean dose of atorvastatin, mg | 36.2 ± 11.8a | 40.3 ± 17.0 | 0.286 |
Antiplatelets, n (%) | 30 (100) | 29 (100) | – |
Dual-antiplatelet therapy, n (%) | 4 (13.3) | 11 (37.9) | 0.031 |
Oral anti-diabetics, n (%) | 4 (13.3) | 7 (24.1) | 0.287 |
ECG Exercise test | |||
Exercise duration, sec | 350.1 ± 133.1 | 370.4 ± 131.0 | 0.558 |